BioPharma Credit Plc Enters Into A Definitive Senior Secured Note Purchase Agreement

BioPharma Credit Plc (LSE: BPCR), has entered into a definitive senior secured note purchase agreement for issuance and sale by OptiNose US, Inc, a wholly-owned subsidiary of OptiNose along with BioPharma Credit Investments V LP, Inc. The agreement is for the sale of senior secured notes in an aggregate original principal amount of up to US$150 million. The company will initially invest US$44.0 million, and the company’s share of the transaction will be up to US$82.5 million.

On 13th September 2019, at the time of writing, GMT 08:04 AM, BPCR shares were trading at GBX 1.02, down by 0.005 points or 0.49% against the previous day closing price.